Long-Term Survival in Patients With Advanced Melanoma

Area of Science:

• Oncology
• Immunotherapy
• Clinical Research

Background:

• Long-term survival curves for advanced melanoma patients treated with immune checkpoint inhibitors (ICIs) in clinical trials suggest a plateau, indicating potential for durable responses.
• Real-world data are crucial to validate these findings outside controlled trial environments.

Purpose of the Study:

• To evaluate long-term survival outcomes in patients with advanced melanoma receiving first-line ICIs in a real-world clinical setting.
• To identify factors influencing progression-free survival (PFS) after achieving partial or complete response.

Main Methods:

• A nationwide cohort study utilized prospectively collected data from the Dutch Melanoma Treatment Registry (2012-2019).
• Analysis included 2490 patients treated with first-line ipilimumab-nivolumab, anti-PD-1 antibodies, or ipilimumab.
• Progression-free survival and melanoma-specific survival were analyzed using Cox proportional hazards models.

Main Results:

• Five-year overall survival was 35.9% (95% CI, 33.9%-38.0%) and 5-year progression-free survival was 19.7% (95% CI, 18.0%-21.4%).
• Survival plateaus were observed, comparable to clinical trial data.
• Patients with metastases in three or more organ sites had a higher risk of progression after response (aHR, 1.37; 95% CI, 1.11-1.69).

Conclusions:

• Real-world data confirm that immune checkpoint inhibitors lead to long-term survival plateaus in advanced melanoma patients.
• Findings support the use of these results in clinical practice for surveillance strategies and patient counseling.
• The study highlights the sustained efficacy of ICIs in managing advanced melanoma beyond clinical trial populations.